No quarterly revenue total was found in Bicara Therapeutics Inc.'s SEC filings.
Bicara Therapeutics Inc. (BCAX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$44.3 million. As of Jun 30, 2026 it held $497.3 million in cash and investments and $1.2 million in total debt.
Revenue
—
Net income
$-55.44M
-102.4% vs year-ago quarter
Operating cash flow
$-44.21M
-72.7% vs year-ago quarter
Free cash flow
$-44.27M
-73.0% vs year-ago quarter
EPS
$-0.82
-64.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
66.17M
+21.3% vs year-ago quarter
Net cash
$496.10M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2023658
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$60.0M | -$60.2M | -$41.1M | -$40.7M | -$32.0M |
| Net income | -$55.4M | -$56.2M | -$37.4M | -$36.3M | -$27.4M |
| Diluted EPS | -$0.82 | -$0.93 | -$0.00 | -$0.67 | -$0.50 |
| Operating cash flow | -$44.2M | -$37.5M | -$23.9M | -$29.2M | -$25.6M |
| Free cash flow | -$44.3M | -$37.6M | -$24.1M | -$29.3M | -$25.6M |
| Total assets | $512.2M | $553.6M | $431.0M | $424.7M | $453.6M |
| Total liabilities | $43.5M | $39.6M | $29.5M | $21.9M | $18.4M |
| Stockholders' equity | $468.8M | $514.0M | $401.5M | $402.8M | $435.2M |
| Cash and investments | $497.3M | $539.8M | $414.8M | $407.6M | $436.6M |
| Total debt | $1.2M | $1.4M | $1.7M | $2.0M | $2.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Aug 25, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 28, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
All 263 Bicara Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.